Cargando…

An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective

Epithelial ovarian cancer (EOC), a primarily high-grade serous carcinoma (HGSOC), is one of the major causes of high death-to-incidence ratios of all gynecological cancers. Cytoreductive surgery and platinum-based chemotherapy represent the main treatments for this aggressive disease. Molecular char...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cordani, Nicoletta, Bianchi, Tommaso, Ammoni, Luca Carlofrancesco, Cortinovis, Diego Luigi, Cazzaniga, Marina Elena, Lissoni, Andrea Alberto, Landoni, Fabio, Canova, Stefania
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418869/ https://www.ncbi.nlm.nih.gov/pubmed/37569269 http://dx.doi.org/10.3390/ijms241511890

Ejemplares similares

Harnessing DLL3 inhibition: From old promises to new therapeutic horizons
por: Cortinovis, Diego Luigi, et al.
Publicado: (2022)

Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything
por: Capici, Serena, et al.
Publicado: (2022)

Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience
por: Monaco, Lavinia, et al.
Publicado: (2021)

Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment?
por: Putzu, Carlo, et al.
Publicado: (2023)

Novel Therapeutic Options for Small Cell Lung Cancer
por: Canova, Stefania, et al.
Publicado: (2023)

Focus on Nivolumab in NSCLC
por: Cortinovis, Diego L., et al.
Publicado: (2016)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

Metronomic Chemotherapy
por: Cazzaniga, Marina Elena, et al.
Publicado: (2021)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

An Overview of PARP Inhibitors for the Treatment of Breast Cancer
por: Cortesi, Laura, et al.
Publicado: (2021)

Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma
por: Cortinovis, Diego, et al.
Publicado: (2021)

Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows
por: Cazzaniga, Marina Elena, et al.
Publicado: (2022)

PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

Sneaky Diagnosis of Pleural Malignant Mesothelioma in Thoracic Surgery: All That Glitters Is Not Gold
por: Orlandi, Riccardo, et al.
Publicado: (2022)

Targeted therapies and immunotherapy in non-small-cell lung cancer
por: Cortinovis, D, et al.
Publicado: (2016)

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
por: Boussios, Stergios, et al.
Publicado: (2019)

Integration of PARP-inhibitors in ovarian cancer therapy
por: Pietragalla, Antonella, et al.
Publicado: (2020)

PARP Inhibitors in Ovarian Cancer: A Review
por: O’Malley, David M., et al.
Publicado: (2023)

Chromosome territories, X;Y translocation and Premature Ovarian Failure: is there a relationship?
por: Lissoni, Sara, et al.
Publicado: (2009)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer
por: Ma, Hanlin, et al.
Publicado: (2022)

Clinical Aspects of Sepsis: An Overview
por: Monti, Giacomo, et al.
Publicado: (2014)

New treatment option for ovarian cancer: PARP inhibitors
por: Meehan, Robert S., et al.
Publicado: (2016)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

The role of PARP inhibitor combination therapy in ovarian cancer
por: Hockings, Helen, et al.
Publicado: (2023)

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
por: van Beek, Lotte, et al.
Publicado: (2021)

Radical Hysterectomy in Early-Stage Cervical Cancer: Abandoning the One-Fits-All Concept
por: Bianchi, Tommaso, et al.
Publicado: (2023)

The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer
por: Gien, Lilian T., et al.
Publicado: (2010)

The development of PARP inhibitors in ovarian cancer: from bench to bedside
por: Drew, Yvette
Publicado: (2015)

PARP-1 may be involved in angiogenesis in epithelial ovarian cancer
por: Wei, Wei, et al.
Publicado: (2016)

PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
por: Jiang, Xuan, et al.
Publicado: (2019)

Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
por: Huang, Xuan-zhang, et al.
Publicado: (2020)

PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
por: Miller, Rowan E, et al.
Publicado: (2022)

Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2023)

Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
por: Tang, Bin, et al.
Publicado: (2023)

Human PARP1 substrates and regulators of its catalytic activity: An updated overview
por: Zhu, Tao, et al.
Publicado: (2023)

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
por: Cogliati, Viola, et al.
Publicado: (2022)

Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer
por: Paracchini, Lara, et al.
Publicado: (2022)

Advances and perspectives of PARP inhibitors
por: Yi, Ming, et al.
Publicado: (2019)

Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy
por: Fumagalli, Caterina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f6e37q8a5dgdlpqj9il5964ruk